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A Policy Impact Analysis of the
Mandatory NCAA Sickle Cell
Trait Screening Program
Beth A. Tarini, Margaret Alison Brooks, and David G. Bundy
Objective. To estimate the impact of the mandatory National Collegiate Athletic
Association (NCAA) sickle cell trait (SCT) screening policy on the identiﬁcation of
sickle cell carriers and prevention of sudden death.
Data Source. We used NCAA reports, population-based SCT prevalence estimates,
and published risks for exercise-related sudden death attributable to SCT.
Study Design. We estimated the number of sickle cell carriers identiﬁed and the num-
ber of potentially preventable sudden deaths with mandatory SCTscreening of NCAA
Division I athletes. We calculated the number of student-athletes with SCTusing a con-
ditional probability based upon SCT prevalence data and self-identiﬁed race/ethnicity
status. We estimated sudden deaths over 10 years based on published attributable risk
of exercise-related sudden death due to SCT.
Principal Findings. We estimate that over 2,000 NCAA Division I student-athletes
with SCTwill be identiﬁed under this screening policy and that, without intervention,
about seven NCAA Division I student-athletes would die suddenly as a complication
of SCTover a 10-year period.
Conclusion. Universal sickle cell screening of NCAA Division I student-athletes will
identify a substantial number of sickle cell carriers. A successful intervention could pre-
vent about seven deaths over a decade.
Key Words. Sickle cell trait, National Collegiate Athletic Association, screening,
sudden death, athletes
On August 1, 2010, the National Collegiate Athletic Association (NCAA)
implemented one of the largest mandated genetic screening programs in the
United States: universal sickle cell trait (SCT) screening of all Division I
student-athletes (NCAA 2010b). The policy resulted from a legal settlement
with the family of Dale Lloyd II, a Rice University football player, who
collapsed during football practice and later died from acute exertional
rhabdomyolysis attributed to SCT (Figure 1).
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The morbidity associated with SCT has long been debated (Sears 1978).
Complications of SCTare rare and include infarction associated with hypoxia
from high altitudes and renal medullary carcinoma (Tsaras et al. 2009). How-
ever, there is also concern that athletes with SCT have an elevated risk of exer-
cise-related sudden death secondary to exertional heat illness or acute
exertional rhabdomyolysis (Eichner 2010).
The NCAA’s mandatory, universal SCT screening program (NCAA
Proposal No. 2009-75-B) has sparked signiﬁcant debate. Endorsement of
this policy from professional organizations has been mixed (College of
American Pathologists 2007; National Athletic Trainers’ Association 2007;
Secretary’s Advisory Committee on Heritable Disorders and Genetic Dis-
eases in Newborns and Children’s 2010). This is due to fear that screening
may lead to discrimination and confusion (Bonham, Dover, and Brody
2010), as occurred with previous community and public health sickle cell
screening programs (Whitten 1973; Rutkow and Lipton 1974), as well as a
paucity of evidence that screening improves health outcomes for student-
athletes.
Given the scope and controversy of the screening program, we con-
ducted a policy impact analysis (Porell and Adams 1995) to estimate the num-
ber of athletes with SCT identiﬁed and the anticipated number of exercise-
related sudden deaths attributable to SCTamongNCAA student-athletes.
Figure 1: Timeline of Signiﬁcant Events in the Implementation of NCAA
Division I Sickle Cell Screening Program
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METHODS
Study Population: Number of Student-Athletes
We used the most recently published, publicly available NCAA participation
rates (academic year 2007–2008) to estimate the number of Division I stu-
dent-athletes in a 4-year cohort (e.g., all participating student-athletes in an
academic year) (NCAA 2009). These data are self-reported by the 335 NCAA
Division I member institutions (National Collegiate Athletic Association
2011).
The NCAAdeﬁnes student-athletes as individuals who meet at least one
of the following criteria by the ﬁrst scheduled competition: (1) are listed as a
team member, (2) practice with the varsity team and receive coaching from
one or more varsity coaches, or (3) receive athletically related student aid. If a
student participates in more than one sport, the NCAA counts him/her as a
student-athlete participant for each sport. However, we are unaware of any
publicly available NCAA statistics on the number of multisport student-ath-
letes. To decrease the likelihood of double-counting athletes, we assumed as
follows: (1) athletes who competed in cross-country also competed in track
and (2) athletes who competed in indoor track also competed in outdoor track
and so only included participants in outdoor track (i.e., did not include partici-
pants listed for cross country and indoor track) in our analyses.
The NCAA assigns sports to one of three categories: championship
(men and women, e.g., basketball), nonchampionship (men only, e.g.,
rowing), and emerging (women only, e.g., rugby). The NCAA policy does not
explicitly exempt student-athletes in nonchampionship and emerging sports
from screening, so we included these athletes in our overall calculation of
“screen-able” student-athletes. Moreover, the NCAA requires that “the [medi-
cal] examination or evaluation [which includes a sickle cell solubility test]
must have been administered within six months prior to participation in any
weight-training or conditioning activity” (NCAA 2010b). As all athletic activi-
ties involve weight-training or conditioning activity, student-athletes in all
three NCAA sport categories meet criteria for SCTscreening.
Study Population: Race/Ethnicity of Student-Athletes
Because the prevalence of SCT is increased in Black and Hispanic/Latino
individuals compared to Whites (Blacks: 1/14, Hispanic/Latino: 1/183,
Whites: 1/625) (Lorey, Arnopp, and Cunningham 1996), we gathered data
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on the race/ethnicity distribution among all NCAA Division I student-ath-
etes for the years 2007–2008 (NCAA 2010a). These data are self-reported by
athletes. The NCAA categorizes race/ethnicity as follows: American Indian/
Alaskan Native, Asian, Black/African American, Hispanic/Latino, Native
Hawaiian/Paciﬁc Islander, Other, Two or More Races, White/Non-Hispanic.
“Black, Non-Hispanic” was deﬁned as “A person having origins in any of the
black racial groups of Africa (except those of Hispanic origin)”; “Hispanic/
Latino” was deﬁned as “a person of Mexican, Puerto Rican, Cuban, Central
or South American or other Spanish culture or origin, regardless of race”
(NCAA 2010a). We collapsed these categories as follows (Lorey, Arnopp,
and Cunningham 1996): Black, Non-Hispanic; Hispanic; All Other.
Prevalence of SCT
Literature-derived estimates for the prevalence of SCT vary by ethnicity. Clas-
sically, discussion of the prevalence of SCT has focused exclusively on indi-
viduals of African ancestry. However, studies report an increased prevalence
in Hispanics/Latinos compared to individuals of non-Hispanic/non-African
ancestry. We used the following published point estimates for prevalence: 7
percent of blacks, 0.5 percent of Hispanics/Latinos, and 0.2 percent of whites
(Lorey, Arnopp, and Cunningham 1996). We applied the 0.2 percent preva-
lence for whites to our “Other” race/ethnicity category.
Rates of Death for Exercise-Related Sudden Death from SCT
We identiﬁed only one study that systematically quantiﬁes the risk of exer-
cise-related sudden death associated with SCT. It was conducted in U.S.
military recruits and categorized reasons for death into three categories:
sudden unexplained death, sudden nonunexplained death (e.g., silent struc-
tural heart disease, asthma), nonsudden death (Kark et al. 1987). “Sudden
death” was deﬁned as “death due to an illness producing an irreversible crit-
ical condition within 1 hour of onset.” The authors categorized exertional
heat stress, heat stroke, rhabdomyolysis, and unknown mechanism as “sud-
den unexplained death.” We used the death rate for “sudden unexplained
death” in our analyses because it included hypothesized mechanisms (e.g.,
exertional heat stress, rhabdomyolysis) of exercise-related sudden death
among individuals with SCT (Eichner 2010). For the risk of sudden death
due to SCT in our analysis, we used the attributable death rates for sudden
death among black recruits (31 deaths per 100,000 individuals) with SCT,
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calculated by subtracting the death rate among black recruits with
SCT (32.2 per 100,000) from the death rate among black recruits without
SCT (1.2 per 100,000).
Analysis
To estimate the number of student-athletes who would suffer exercise-related
sudden death due to SCT, we calculated the conditional probability of an
exercise-related sudden death for student-athletes based upon the likelihood
of an athlete having SCT. We assumed full compliance of all Division I mem-
ber institutions with this mandatory screening policy.
Number of Athletes with SCT. First, we calculated the conditional probability of
having SCT based upon ethnic group status, stratiﬁed by sport and by gender:
P ðHaving SCT Þ ¼ P ðRace=EthnicityÞ  P ðSickle cell trait given race=ethnicityÞ
We multiplied this probability by the number of Division I student-
athletes in a 4-year cohort to estimate the number of individuals who have
SCT among all Division I student-athletes. We multiplied this estimate by
the sensitivity of the sickle cell solubility test (98.9 percent) to determine the
number of athletes with SCT identiﬁed by testing (Hicks and Hughes 1975).
We then divided our total student body estimate by 4 to determine the
number of athletes with SCT identiﬁed in each academic class (i.e., those
identiﬁed annually).
Number of Sudden Deaths Attributable to SCT. We estimated the probability of
exercise-related death from SCT conditioned upon the likelihood of having
SCT, using published risk estimates (Kark et al. 1987):
P ðDeath=SCT Þ ¼ P ðDeath among individuals with SCT Þ  P ðHaving SCT Þ
To estimate the number of expected sudden deaths in an academic year,
we multiplied this probability by the number of Division I athletes participat-
ing in each sport during an academic year (i.e., 4-year cohort). We used this
statistic because each year every participating athlete (newly identiﬁed SCTor
already known) is at risk of sudden death from SCT. We multiplied the
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number of deaths by 10 to estimate deaths over a 10-year time period, which
allowed us to benchmark our model against estimates of sudden death attrib-
utable to SCT based on case reports.
Although female athletes anecdotally constitute a lower proportion of
exercise-related death cases related to SCT thanmale athletes, we are unaware
of any published data conﬁrming this and so did not apply a gender-based dif-
ferential probability of death.
Number Needed to Screen and Cost of Testing. Finally, we calculated the number
needed to screen (NNS) to prevent one student-athlete death from SCT
(assuming a 100 percent effective intervention). Because our data do not pro-
vide the athlete’s eligibility year, we calculated the NNS over a 4-year period
by assuming that ¼ of participants represented a freshman class that would
only be screened once during this 4-year period.
The NCAA policy recommends that athletes be screened with a sickle
cell solubility test (National Collegiate Athletic Association 2010). Positive
sickle cell solubility tests must be conﬁrmed with hemoglobin (Hb) electro-
phoresis. We calculated the number of student-athletes with positive sickle cell
solubility tests that would undergo Hb electrophoresis bymultiplying the pub-
lished sensitivity estimate of 98.9 percent for sickle cell solubility testing by
the number of athletes with SCT in the total athletic student body (Table 1).
We did not examine the costs for false-positive results since the published
speciﬁcity estimate for sickle cell solubility testing is 100 percent (Hicks and
Hughes 1975). To calculate the cost of screening and conﬁrmatory testing
alone (excluding education and counseling costs), we used a range of costs for
the sickle cell solubility testing ($10–$20) provided by different collegiate
institutions (Secretary’s Advisory Committee on Heritable Disorders in
Newborns Meeting 2010; University of California-Berkeley 2010; Wesleyan
University 2010). We used $50 for the cost of hemoglobin electrophoresis
(Chasen, Loeb-Zeitlin, and Landsberger 1999; January 22, 2010).
RESULTS
In the 2007–2008 season, 81,073 male and 63,108 female student-athletes
participated in NCAA Division I sports. Football (n = 25,658) had the most
participants for men’s sports and track for women’s sports (n = 11,230)
(Appendix SA2, Supporting Information). Overall, the majority of Division I
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student-athletes self-reported a non-Black, non-Hispanic/Latino race/ethnic-
ity (male 71.1 percent, female 80.4 percent, Appendix SA3).
Among the estimated 2,147 athletes with SCT, we estimate that 2,123
NCAA Division I student-athletes in one 4-year cohort of athletes (i.e., total
athletic student body) would be identiﬁed as having SCT under this new
screening policy (about 530 new students annually) (Table 1). Of these, 89
percent will self-report as Black race/ethnicity. Most student-athletes with
SCT will compete in football (n = 863), track (n = 463), and basketball
(n = 393).
Table 1: Estimated Number of Division I NCAA Student-Athletes with
Sickle Cell Trait
Black Hispanic Other Total
Archery 0 0 0 0
Badminton 0 0 0 0
Baseball 43 3 18 64
Basketball 384 1 9 393
Bowling 9 0 0 9
Equestrian 0 0 1 2
Fencing 3 0 1 4
Field hockey 2 0 3 6
Football 833 3 26 863
Golf 13 1 9 23
Gymnastics 5 0 3 8
Ice hockey 1 0 5 6
Lacrosse 6 0 9 16
Riﬂe 0 0 1 1
Rowing 11 1 12 24
Rugby 0 0 0 0
Sailing 0 0 0 0
Skiing 0 0 1 1
Soccer 68 4 23 95
Softball 28 2 9 39
Squash 0 0 1 1
Swimming/diving 8 1 17 26
Sync. swimming 0 0 0 0
Team handball 0 0 0 0
Tennis 22 2 10 34
Track, outdoor 430 4 29 463
Volleyball 40 1 9 50
Water polo 1 0 2 4
Wrestling 11 1 5 16
All sports 1,918 25 204 2,147*
*This number is multiplied by 0.989 to calculate the number of athletes identiﬁed by sickle cell sol-
ubility testing = 2,123 athletes.
452 HSR: Health Services Research 47:1, Part II (February 2012)
In a 4-year cohort of screened NCAA student-athletes (e.g., a 4-year per-
iod with each athlete screened only once), there would be one death. Based on
our model, we estimated that without intervention, about seven student-ath-
letes with SCTwould suffer exercise-related sudden death by year 10 of the
screening program (Table 2).
Assuming a 100 percent effective intervention, this screening program
requires that 144,181 student-athletes (e.g., a 4-year cohort of athletes) be
screened to prevent one death. For each death prevented, we estimate that the
cost of testing alone (i.e., without education or counseling) would range from
$1,441,810 to $2,883,620 for sickle cell solubility testing and be about
$106,150 for hemoglobin electrophoresis conﬁrmatory testing for those with
positive sickle cell solubility tests.
DISCUSSION
The NCAA recently implemented mandatory SCTscreening of all Division I
student-athletes. Using publicly available data, we estimated that this policy
would identify over 2,000 athletes with SCTamong a 4-year cohort of student-
athletes. Alongside a 100 percent effective intervention, screening could pre-
vent the deaths of seven student athletes over a 10-year period. Our estimate
approximates the number of case reports of collegiate student-athletes that
have suffered exercise-related death attributed to SCTover a similar historical
time interval (Eichner 2010, 2011).
A powerful motivating force behind the mandatory NCAA SCTscreen-
ing policy was a wrongful death suit. As part of the settlement, the NCAA
agreed to require that all Division I athletes be screened for SCT before
sports participation (Lanier Law Firm 2009). Previously, the NCAA had
recommended, but not required, that member institutions screen athletes for
SCT (NCAA 2008b); compliance from member institutions had been vari-
able (Clarke et al. 2006).
The NCAA SCTscreening policy yields interesting comparisons to the
controversy surrounding cardiovascular screening of college athletes to pre-
vent sudden death. The NCAA does not currently recommend universal
ECG screening for student athletes despite the fact that cardiovascular condi-
tions underlie more than half of medically related sudden deaths among col-
lege athletes (Harmon et al. 2011) and data exist to support the notion that
ECG screening may reduce the incidence of cardiovascular sudden death
(Corrado et al. 1998). Admittedly, issues remain to be resolved (e.g., nontrivial
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incidence and consequence of false-positive test results, uncertainty that
screening would lead to a reduction in the number of deaths from cardiovas-
cular causes). However, a reasonable argument could be made that the evi-
dence base supporting an NCAA recommendation for universal ECG
screening appears more robust than that for universal SCTscreening.
The relationship between exercise-related death and SCT has long been
debated. While ample evidence suggests that SCT has not limited the compet-
itiveness of professional football players (Murphy 1973), national track cham-
pions (Pearson 1989; Bile et al. 1998), or elite sprinters (Marlin et al. 2005),
case reports of exercise-related sudden death in athletes with SCTat all levels
Table 2: Estimated Exercise-Related Deaths from Sickle Cell Trait in
NCAADivision I Student-Athletes ThatWould Be Prevented over 10 Years
Deaths
Archery 0.0
Badminton 0.0
Baseball 0.2
Basketball 1.2
Bowling 0.0
Equestrian 0.0
Fencing 0.0
Field hockey 0.0
Football 2.7
Golf 0.1
Gymnastics 0.0
Ice hockey 0.0
Lacrosse 0.0
Riﬂe 0.0
Rowing 0.1
Rugby 0.0
Sailing 0.0
Skiing 0.0
Soccer 0.2
Softball 0.1
Squash 0.0
Swimming/diving 0.1
Sync. swimming 0.0
Team handball 0.0
Tennis 0.1
Track, outdoor 1.4
Volleyball 0.2
Water polo 0.0
Wrestling 0.1
All sports 6.5
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of sports (e.g., high school through professional) suggest a compelling pattern.
Exercise-related sudden deaths attributed to SCT tend to occur in male ath-
letes, early in training (often on the ﬁrst day), and during conditioning work-
outs. They tend to be associated with high levels of exertion, such as short,
maximum-effort drills/testing, such as those frequently used in football, a
sport in which numerous sudden deaths have been attributed to SCT (Eichner
2010, 2011). Environmental conditions, such as the heat and hydration status
of the player, also play an important role. These data suggest that a gene–envi-
ronment interaction promotes the initiation of acidosis and rhabdomyolysis
that triggers sickling and creates a rapid downward spiral fromwhich recovery
is difﬁcult (Eichner 2010).
The “treatment” for the athlete with SCT is proactive prevention that
focuses on appropriate preseason and in-season conditioning. To this end, the
NCAA recommends a number of precautionary strategies for athletes with
SCT (Figure 2). There is evidence that preventive hydration and temperature-
monitoring strategies are effective. A 1970s study of U.S. military recruits
found an increase in unexplained sudden death among individuals with SCT,
compared to those without (Kark et al. 1987). However, unlike the NCAA,
the U.S. military implemented universal intervention rather than screening. In an
experimental study of universal precautionary measures (e.g., aggressive
hydration, temperature monitoring) without a priori knowledge of recruits’
SCT status, the military was able to prevent all subsequent sudden death in
recruits with SCT (Kark et al. 1999). This universal intervention program
may yield positive spillover effects to other life-threatening conditions unre-
lated to SCT (e.g., exertional heat stroke) that beneﬁt all athletes, not just those
with SCT.
Of course, successful screening programs depend upon effective and
accessible interventions. It is unclear how the NCAA enforces compliance
with its “safe conditioning” recommendation and there does not seem to be a
strong mandate for intervention. The NCAA informs athletes and member
institutions that “Student-athletes with SCTshould be knowledgeable of these
precautions and institutions should provide an environment in which these
precautions may be activated” (2008a). However, the ongoing challenge of
compliance with sports-related concussion guidelines highlights the power of
the “pressure to play” after an individual is identiﬁed as being at risk for
sports-related injury. Such pressure to perform and dismiss early symptoms is
likely no different for student-athletes with SCT. For example, in 2008 a colle-
giate football player died during a football-conditioning workout despite the
fact that he and the athletic staff were aware that he had SCT. He had reportedly
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tested positive for SCT twice in 2007 (Fainaru-Wada 2008)—highlighting that
screening can lead to a false sense of security if an effective intervention is not
enforced.
Although the NCAA policy may be based more litigation based, rather
than evidence based, it has real-life implications for the athletes and schools
forced to comply with it. First, there are economic costs to the member institu-
tions that must carry out the education and testing. Second, there is the poten-
tial for discrimination toward athletes both during and after their collegiate
Set their own pace. 
Engage in a slow and gradual pre-season conditioning regimen 
to be prepared for sports-specific performance testing and the 
rigors of competitive intercollegiate athletics. 
Build up slowly while training (e.g., paced progressions). 
Use adequate rest and recovery between repetitions, especially 
during “gassers” and intense station or “mat” drills. 
Not be urged to perform all-out exertion of any kind beyond 
2 to 3 minutes without a breather. 
Be excused from performance tests such as serial sprints or 
timed mile runs, especially if these are not normal sport 
activities. 
Stop activity immediately upon struggling or experiencing 
symptoms such as muscle pain, abnormal weakness, undue 
fatigue, or breathlessness. 
Stay well hydrated at all times, especially in hot and humid 
conditions. 
Maintain proper asthma management. 
Refrain from extreme exercise during acute illness, if feeling ill, 
or while experiencing a fever. 
Access supplemental oxygen at altitude as needed. 
Seek prompt medical care when experiencing unusual distress. 
Figure 2: NCAA Recommended Precautions for Student-Athletes with
Sickle Cell Trait (NCAA 2010b)
456 HSR: Health Services Research 47:1, Part II (February 2012)
athletic careers. While precautions should be taken, athletic programs should
not exclude these athletes or discourage them from being competitive, but
rather, according to the NCAA “enable them to thrive in their sport” (2008a).
Similarly, when some of these student-athletes transition to professional athlet-
ics, coaches and athletic directors should ensure that athletes with SCT do not
suffer employment discrimination due to their genetic status. The history of
screening for SCT is littered with stories of misinformation, stigma, and unjus-
tiﬁed exclusion from activities and professions (Levin 1958;Whitten 1973).
Our policy analysis has limitations. First, NCAADivision II and III ath-
letes are also at risk for exercise-related sudden death due to SCT. While they
comprise a signiﬁcant proportion (61 percent) of collegiate athletes, we did not
include them in our formal analyses because the current NCAA SCTscreen-
ing policy is limited to Division I athletes. Using identical methods, we calcu-
lated that 1,210 Division II and 675 Division III athletes would be identiﬁed as
having SCT (Appendices SA4 and SA5). Assuming an effective intervention,
it will take about 3 years to prevent a death in Division II and over 4 years in
Division III (data not shown). Second, student-athletes that participate in mul-
tiple Division I sports could have been double-counted, leading to an overesti-
mate of individuals with SCT. We have attempted to account for this by only
including athletes who participated in outdoor track (i.e., not indoor track or
cross country). Although some multisport athletes probably remain in our
model, their effect on our results should be small and lead to only a slight over-
estimation of sudden deaths. Third, testing costs are based on publicly avail-
able costs provided to student-athletes by institutions and probably vary
across institutions. However, we feel that the testing cost estimates used in our
analysis are reasonable and illustrate that while the costs of individual tests are
inexpensive, the cost of testing across all student-athletes is not trivial. Finally,
we assumed that Division I college student-athletes do not have a greater or
lesser proportion of individuals with SCT compared to the general popula-
tion. Based on previous studies of elite athletes, we have no reason to believe
that we have overestimated the prevalence of SCT in this population (Murphy
1973; Bile et al. 1998). In fact, a study of elite sprinters found an overrepresen-
tation of individuals with SCTamong title winners (Marlin et al. 2005).
Despite these limitations, we feel that our analysis has important impli-
cations for policy makers. First, it provides data about the scope and impact of
a policy whose implementation was driven by litigation rather than evidence.
Additional studies could explore the scope of screening-related harms, the
costs of screening, and the effectiveness of and compliance with interventions.
A successful screening program consists of both identiﬁcation and action—in
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this case, rigorous compliance with conditioning precautions. Evidence of this
intervention’s effectiveness is sorely needed, because interventions, not screen-
ing tests, save lives. For this screening policy to be successful, testing must be
only the ﬁrst step in the NCAA’s overall strategy. However, the question still
remains whether SCTscreening is a necessary step to prevent exercise-related
sudden death in student-athletes.
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